IL-6 pathway in the liver: From physiopathology to therapy

Journal of Hepatology

Volumn 64, Issue 6, 2016, Pages 1403-1415

  Schmidt Arras, Dirk ^a   Rose John, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Cancer; Inflammation; Interleukin 6; Interleukin 6 receptor; Liver regeneration; Trans signaling

Indexed keywords

GLYCOPROTEIN GP 130; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 1; PROTEIN KINASE FYN; RUXOLITINIB; SILTUXIMAB; STAT3 PROTEIN; TOCILIZUMAB; TOFACITINIB; STAT3 PROTEIN, HUMAN;

ACUTE PHASE RESPONSE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIVER; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER REGENERATION; LIVER TUMOR; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; PHYSIOLOGY;

ACUTE-PHASE REACTION; ANIMALS; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; LIVER; LIVER NEOPLASMS; LIVER REGENERATION; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84963541541     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.02.004     Document Type: Review

References (122)

1. T. Kishimoto IL-6: from its discovery to clinical applications Int Immunol 22 2010 347 352
2. T. Hirano, K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, and et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin Nature 324 1986 73 76
3. T. Kishimoto Interleukin-6: from basic science to medicine-40 years in immunology Annu Rev Immunol 23 2005 1 21
4. F. Schaper, and S. Rose-John Interleukin-6: biology, signaling and strategies of blockade Cytokine Growth Factor Rev 26 2015 475 487
5. J. Müllberg, H. Schooltink, T. Stoyan, M. Günther, L. Graeve, and et al. The soluble interleukin-6 receptor is generated by shedding Eur J Immunol 23 1993 473 480
6. A. Mackiewicz, H. Schooltink, P.C. Heinrich, and S. Rose-John Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins J Immunol 149 1992 2021 2027
7. S. Rose-John, and P.C. Heinrich Soluble receptors for cytokines and growth factors: generation and biological function Biochem J 300 1994 281 290
8. M. Fischer, J. Goldschmitt, C. Peschel, J.P. Brakenhoff, K.J. Kallen, and et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion Nat Biotechnol 15 1997 142 145
9. P. März, J.G. Cheng, R.A. Gadient, P.H. Patterson, T. Stoyan, and et al. Sympathetic neurons can produce and respond to interleukin 6 Proc Natl Acad Sci U S A 95 1998 3251 3256
10. P. März, K. Heese, B. Dimitriades-Schmutz, S. Rose-John, and U. Otten Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression Glia 26 1999 191 200
11. M. Romano, M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, and et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment Immunity 6 1997 315 325
12. M. Klouche, S. Bhakdi, M. Hemmes, and S. Rose-John Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor J Immunol 163 1999 4583 4589
13. J. Audet, C.L. Miller, S. Rose-John, J.M. Piret, and C.J. Eaves Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells Proc Natl Acad Sci U S A 98 2001 1757 1762
14. S. Viswanathan, T. Benatar, S. Rose-John, D.A. Lauffenburger, and P.W. Zandstra Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6 Stem Cells 20 2002 119 138
15. T. Jostock, J. Müllberg, S. Ozbek, R. Atreya, G. Blinn, and et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses Eur J Biochem 268 2001 160 167
16. S. Rose-John IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6 Int J Biol Sci 8 2012 1237 1247
17. J. Scheller, and S. Rose-John The interleukin 6 pathway and atherosclerosis Lancet 380 2012 338
18. C. Garbers, S. Aparicio-Siegmund, and S. Rose-John The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition Curr Opin Immunol 34 2015 75 82
19. J. Gauldie, C. Richards, D. Harnish, P. Lansdorp, and H. Baumann Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells Proc Natl Acad Sci U S A 84 1987 7251 7255
20. H. Baumann, and J. Gauldie The acute phase response Immunol Today 15 1994 74 80
21. C. Gabay, and I. Kushner Acute-phase proteins and other systemic responses to inflammation N Engl J Med 340 1999 448 454
22. J.G. Bode, U. Albrecht, D. Häussinger, P.C. Heinrich, and F. Schaper Hepatic acute phase proteins-regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling Eur J Cell Biol 91 2012 496 505
23. M. Kopf, H. Baumann, G. Freer, M. Freudenberg, M. Lamers, and et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice Nature 368 1994 339 342
24. H. Schooltink, T. Stoyan, E. Roeb, P.C. Heinrich, and S. Rose-John Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes FEBS Lett 314 1992 280 284
25. C.D. Richards, C. Langdon, D. Pennica, and J. Gauldie Murine cardiotrophin-1 stimulates the acute-phase response in rat hepatocytes and H35 hepatoma cells J Interferon Cytokine Res 16 1996 69 75
26. J.J. Morley, and I. Kushner Serum C-reactive protein levels in disease Ann N Y Acad Sci 389 1982 406 418
27. G.K. Michalopoulos, and M.C. DeFrances Liver regeneration Science 276 1997 60 66
28. G.K. Michalopoulos Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas Am J Pathol 176 2010 2 13
29. B. Fisher, P. Szuch, M. Levine, and E.R. Fisher A portal blood factor as the humoral agent in liver regeneration Science 171 1971 575 577
30. C. Trautwein, T. Rakemann, M. Niehof, S. Rose-John, and M.P. Manns Acute-phase response factor, increased binding, and target gene transcription during liver regeneration Gastroenterology 110 1996 1854 1862
31. R. Taub Liver regeneration: from myth to mechanism Nat Rev Mol Cell Biol 5 2004 836 847
32. D.E. Cressman, L.E. Greenbaum, R.A. DeAngelis, G. Ciliberto, E.E. Furth, and et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice Science 274 1996 1379 1383
33. G.C.T. Yeoh, M. Ernst, S. Rose-John, B. Akhurst, C. Payne, and et al. Opposing roles of gp130-mediated STAT-3 and ERK-1/ 2 signaling in liver progenitor cell migration and proliferation Hepatology 45 2007 486 494
34. M. Peters, S. Jacobs, M. Ehlers, P. Vollmer, J. Müllberg, and et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6 J Exp Med 183 1996 1399 1406
35. M. Peters, P. Schirmacher, J. Goldschmitt, M. Odenthal, C. Peschel, and et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice J Exp Med 185 1997 755 766
36. P. Schirmacher, M. Peters, G. Ciliberto, M. Blessing, J. Lotz, and et al. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice Am J Pathol 153 1998 639 648
37. M. Peters, G. Blinn, T. Jostock, P. Schirmacher, K.H. Meyer zum Büschenfelde, and et al. Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration Gastroenterology 119 2000 1663 1671
38. E. Galun, E. Zeira, O. Pappo, M. Peters, and S. Rose-John Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury FASEB J 14 2000 1979 1987
39. N. Hecht, O. Pappo, D. Shouval, S. Rose-John, E. Galun, and et al. Hyper-IL-6 gene therapy reverses fulminant hepatic failure Mol Ther 3 2001 683 687
40. S.A. Jones, and S. Rose-John The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex Biochim Biophys Acta 1592 2002 251 263
41. M. Peters, G. Blinn, F. Solem, M. Fischer, K.H. Meyer zum Büschenfelde, and et al. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6 J Immunol 161 1998 3575 3581
42. E. Galun, and S. Rose-John The regenerative activity of interleukin-6 Methods Mol Biol 982 2013 59 77
43. B. Rabe, A. Chalaris, U. May, G.H. Waetzig, D. Seegert, and et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation Blood 111 2008 1021 1028
44. C. Drucker, B. Rabe, A. Chalaris, E. Schulz, J. Scheller, and et al. Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamine-induced liver damage J Interferon Cytokine Res 29 2009 711 718
45. J. Gewiese-Rabsch, C. Drucker, S. Malchow, J. Scheller, and S. Rose-John Role of IL-6 trans-signaling in CCl induced liver damage Biochim Biophys Acta 1802 2010 1054 1061
46. S. Malchow, W. Thaiss, N. Jänner, G.H. Waetzig, J. Gewiese-Rabsch, and et al. Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling Biochim Biophys Acta 1812 2011 290 301
47. C. Drucker, J. Gewiese, and S. Malchow Scheller Jü and Rose-John S, Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration J Autoimmun 34 2010 29 37
48. K. Taniguchi, L.-W. Wu, S.I. Grivennikov, P.R. de Jong, I. Lian, and et al. A gp130-Src-YAP module links inflammation to epithelial regeneration Nature 519 2015 57 62
49. R. Weiss, J. Dziura, T.S. Burgert, W.V. Tamborlane, S.E. Taksali, and et al. Obesity and the metabolic syndrome in children and adolescents N Engl J Med 350 2004 2362 2374
50. A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 2001 327 334
51. T. Matsubara, A. Mita, K. Minami, T. Hosooka, S. Kitazawa, and et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue Cell Metab 15 2012 38 50
52. G. Sabio, M. Das, A. Mora, Z. Zhang, J.Y. Jun, and et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance Science 322 2008 1539 1543
53. H.-J. Kim, T. Higashimori, S.-Y. Park, H. Choi, J. Dong, and et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo Diabetes 53 2004 1060 1067
54. K. Ueki, T. Kondo, and C.R. Kahn Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms Mol Cell Biol 24 2004 5434 5446
55. S.B. Jorgensen, H.M. O'Neill, L. Sylow, J. Honeyman, K.A. Hewitt, and et al. Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity Diabetes 62 2013 56 64
56. F. Mashili, A.V. Chibalin, A. Krook, and J.R. Zierath Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes Diabetes 62 2013 457 465
57. V. Wallenius, K. Wallenius, B. Ahrén, M. Rudling, H. Carlsten, and et al. Interleukin-6-deficient mice develop mature-onset obesity Nat Med 8 2002 75 79
58. V.B. Matthews, T.L. Allen, S. Risis, M.H.S. Chan, D.C. Henstridge, and et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance Diabetologia 53 2010 2431 2441
59. F.T. Wunderlich, P. Ströhle, A.C. Könner, S. Gruber, S. Tovar, and et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action Cell Metab 12 2010 237 249
60. H. Inoue, W. Ogawa, M. Ozaki, S. Haga, M. Matsumoto, and et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo Nat Med 10 2004 168 174
61. D.C. Kroy, N. Beraza, D.F. Tschaharganeh, L.E. Sander, S. Erschfeld, and et al. Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice Hepatology 51 2010 463 473
62. P. Ramadoss, N.E. Unger-Smith, F.S. Lam, and A.N. Hollenberg STAT3 targets the regulatory regions of gluconeogenic genes in vivo Mol Endocrinol 23 2009 827 837
63. M. Awazawa, K. Ueki, K. Inabe, T. Yamauchi, N. Kubota, and et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway Cell Metab 13 2011 401 412
64. J. Mauer, B. Chaurasia, J. Goldau, M.C. Vogt, J. Ruud, and et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin Nat Immunol 15 2014 423 430
65. B.K. Pedersen, and M.A. Febbraio Muscles, exercise and obesity: skeletal muscle as a secretory organ Nat Rev Endocrinol 8 2012 457 465
66. A.C. Könner, R. Janoschek, L. Plum, S.D. Jordan, E. Rother, and et al. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production Cell Metab 5 2007 438 449
67. I.L. Campbell, M. Erta, S.L. Lim, R. Frausto, U. May, and et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain J Neurosci 34 2014 2503 2513
68. M.J. Kraakman, H.L. Kammoun, T.L. Allen, V. Deswaerte, D.C. Henstridge, and et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance Cell Metab 21 2015 403 416
69. Y. Sun, K. Tokushige, E. Isono, K. Yamauchi, and H. Obata Elevated serum interleukin-6 levels in patients with acute hepatitis J Clin Immunol 12 1992 197 200
70. J. Deviere, J. Content, C. Denys, P. Vandenbussche, L. Schandene, and et al. High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production Clin Exp Immunol 77 1989 221 225
71. S. Kakumu, T. Shinagawa, T. Ishikawa, K. Yoshioka, T. Wakita, and et al. Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis Gastroenterol Jpn 28 1993 18 24
72. K. Aleksandrova, H. Boeing, U. Nöthlings, M. Jenab, V. Fedirko, and et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer Hepatology 60 2014 858 871
73. M. Soresi, L. Giannitrapani, F. D'Antona, A.-M. Florena, E. La Spada, and et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma World J Gastroenterol 12 2006 2563 2568
74. S. Maeda, H. Kamata, J.-L. Luo, H. Leffert, and M. Karin IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis Cell 121 2005 977 990
75. W.E. Naugler, T. Sakurai, S. Kim, S. Maeda, K. Kim, and et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production Science 317 2007 121 124
76. H. Lanaya, A. Natarajan, K. Komposch, L. Li, N. Amberg, and et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma∼formation Nat Cell Biol 16 2014 1 7
77. M. Hatting, M. Spannbauer, J. Peng, M. Al Masaoudi, G. Sellge, and et al. Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model Cell Death Dis 6 2015 e1667
78. E. Pikarsky, R.M. Porat, I. Stein, R. Abramovitch, S. Amit, and et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer Nature 431 2004 461 466
79. M. Mair, G. Zollner, D. Schneller, M. Musteanu, P. Fickert, and et al. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis Gastroenterology 138 2010 2499 2508
80. A. Aravinthan, C. Scarpini, P. Tachtatzis, S. Verma, S. Penrhyn-Lowe, and et al. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease J Hepatol 58 2013 549 556
81. A.D. Aravinthan, and G.J.M. Alexander Hepatocyte senescence explains conjugated bilirubinaemia in chronic liver failure J Hepatol 63 2015 532 533
82. J.H. Tabibian, S.P. O'Hara, P.L. Splinter, C.E. Trussoni, and N.F. LaRusso Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis Hepatology 59 2014 2263 2275
83. S. Gao, A. Li, F. Liu, F. Chen, M. Williams, and et al. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma Cancer Cell 24 2013 725 737
84. E.J. Park, J.H. Lee, G.-Y. Yu, G. He, S.R. Ali, and et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression Cell 140 2010 197 208
85. S. Gruber, B.K. Straub, P.J. Ackermann, C.M. Wunderlich, J. Mauer, and et al. Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6Rα signaling Cell Rep 4 2013 669 680
86. S. Wan, E. Zhao, I. Kryczek, L. Vatan, A. Sadovskaya, and et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells Gastroenterology 147 2014 1393 1404
87. S. Finkin, D. Yuan, I. Stein, K. Taniguchi, A. Weber, and et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma Nat Immunol 16 12 2015 1235 1244
88. B.D. Tarlow, C. Pelz, W.E. Naugler, L. Wakefield, E.M. Wilson, and et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes Cell Stem Cell 15 2014 605 618
89. X. Mu, R. Español-Suñer, I. Mederacke, S. Affò, R. Manco, and et al. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment J Clin Invest 125 2015 3891 3903
90. G. He, D. Dhar, H. Nakagawa, J. Font-Burgada, H. Ogata, and et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling Cell 155 2013 384 396
91. D. Iliopoulos, H.A. Hirsch, G. Wang, and K. Struhl Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion Proc Natl Acad Sci U S A 108 2011 1397 1402
92. S. Rebouissou, M. Amessou, G. Couchy, K. Poussin, S. Imbeaud, and et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours Nature 457 2009 200 204
93. C. Pilati, M. Amessou, M.P. Bihl, C. Balabaud, J.T.V. Nhieu, and et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas J Exp Med 208 2011 1359 1366
94. A. Schütt, M. Zacharias, N. Schneider, S. Horn, J. Grötzinger, and et al. Gp130 activation is regulated by D2-D3 interdomain connectivity Biochem J 450 2013 487 496
95. D. Maione, E. Di Carlo, W. Li, P. Musiani, A. Modesti, and et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver EMBO J 17 1998 5588 5597
96. D. Schmidt-Arras, M. Müller, M. Stevanovic, S. Horn, A. Schütt, and et al. Oncogenic deletion mutants of gp130 signal from intracellular compartments J Cell Sci 127 2014 341 353
97. W.-Y. Lu, T.G. Bird, L. Boulter, A. Tsuchiya, A.M. Cole, and et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity Nat Cell Biol 17 2015 971 983
98. B. Klein, J. Wijdenes, X.G. Zhang, M. Jourdan, J.M. Boiron, and et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia Blood 78 1991 1198 1204
99. E. Angevin, J. Tabernero, E. Elez, S.J. Cohen, R. Bahleda, and et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors Clin Cancer Res 20 2014 2192 2204
100. Z.Y. Lu, J. Brochier, J. Wijdenes, H. Brailly, R. Bataille, and et al. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo Eur J Immunol 22 1992 2819 2824
101. C. Gabay, P. Emery, R. van Vollenhoven, A. Dikranian, R. Alten, and et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Lancet 381 2013 1541 1550
102. N. Nishimoto, and T. Kishimoto Interleukin 6: from bench to bedside Nat Clin Pract Rheumatol 2 2006 619 626
103. N. Nishimoto, Y. Kanakura, K. Aozasa, T. Johkoh, M. Nakamura, and et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease Blood 106 2005 2627 2632
104. G.A. Kennedy, A. Varelias, S. Vuckovic, L. Le Texier, K.H. Gartlan, and et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial Lancet Oncol 15 2014 1451 1459
105. S. Shinriki, H. Jono, K. Ota, M. Ueda, M. Kudo, and et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma Clin Cancer Res 15 2009 5426 5434
106. T. Nagasaki, M. Hara, H. Nakanishi, H. Takahashi, M. Sato, and et al. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction Br J Cancer 110 2014 469 478
107. X. Li, W. Yao, Y. Yuan, P. Chen, B. Li, and et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma Gut 2015 Oct 9. pii: gutjnl-2015-310514
108. M. Petruzzelli, M. Schweiger, R. Schreiber, R. Campos-Olivas, M. Tsoli, and et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia Cell Metab 20 2014 433 447
109. K. Ando, F. Takahashi, S. Motojima, K. Nakashima, N. Kaneko, and et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia J Clin Oncol 31 2013 e69 e72
110. J. Hoge, I. Yan, N. Jänner, V. Schumacher, A. Chalaris, and et al. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling J Immunol 190 2013 703 711
111. C.A. Hunter, and S.A. Jones IL-6 as a keystone cytokine in health and disease Nat Immunol 16 2015 448 457
112. S. Vandevyver, L. Dejager, R.E. Vandenbroucke, and C. Libert An acute phase protein ready to go therapeutic for sepsis EMBO Mol Med 6 2014 2 3
113. Z. Kaner, D.E. Ochayon, G. Shahaf, B.M. Baranovski, N. Bahar, and et al. Acute phase protein α1-antitrypsin reduces the bacterial burden in mice by selective modulation of innate cell responses J Infect Dis 211 2015 1489 1498
114. M. Hösel, M. Quasdorff, K. Wiegmann, D. Webb, U. Zedler, and et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection Hepatology 50 2009 1773 1782
115. A. Berti, F. Boccalatte, M.G. Sabbadini, and L. Dagna Assessment of tocilizumab in the treatment of cancer cachexia J Clin Oncol 31 2013 2970
116. L.H. Calabrese, and S. Rose-John IL-6 biology: implications for clinical targeting in rheumatic disease Nat Rev Rheumatol 10 2014 720 727
117. A. Quintás-Cardama, and S. Verstovsek Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance Clin Cancer Res 19 2013 1933 1940
118. H.L. Geyer, and R.A. Mesa Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood 124 2014 3529 3537
119. X. Wang, P.J. Crowe, D. Goldstein, and J.-L. Yang STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review) Int J Oncol 41 2012 1181 1191
120. G.S. Wilson, A. Tian, L. Hebbard, W. Duan, J. George, and et al. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro Cancer Lett 341 2013 224 230
121. C.D. Mohan, H. Bharathkumar, K.C. Bulusu, V. Pandey, S. Rangappa, and et al. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo J Biol Chem 289 2014 34296 34307
122. K. Poussin, C. Pilati, G. Couchy, J. Calderaro, P. Bioulac-Sage, and et al. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma Oncoimmunology 2 2013 e27090